Open an account

Caribou Biosciences

CRBU · NASDAQ

$0.519+$0.055 (+11.85%)TodayMarket closed ·
Prev close $0.464

About CRBU

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Employees
97
Headquarters
Berkeley, California
Listed
Jul 23, 2021
Sector
Health Care
Industry
Biotechnology
Website
cariboubio.com

CRBU key statistics

Market cap
55.64M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.21M
Volume
3.02M
Open price
$0.4694
High today
$0.5254
Low today
$0.4625
52 Week high
$3.54
52 Week low
$0.4425

Caribou Biosciences (CRBU) at a glance

As of Oct 20, 2026, Caribou Biosciences (CRBU) shares are priced at $0.519, giving the company a market cap of 55.64M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.4625 and $0.5254. The current price is 12.2% above the day's low and 1.2% below its high.

Volume so far is 3.02M shares, below the average of 5.21M shares a day.

Over the past year Caribou Biosciences has ranged from $0.4425 to $3.54, and now sits 2% of the way up that range.

Caribou Biosciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.24 per share against an estimate of -$0.3232.

The average analyst price target is $12.09, 2230.3% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 8 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 9 analystsAvg $12.09
Low
$4.04
Now
$0.519
High
$33.60

CRBU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 15.2% on average.

  1. Q3 FY24: reported -$0.38 per share against an estimate of -$0.4585
  2. Q4 FY24: reported -$0.39 per share against an estimate of -$0.4287
  3. Q1 FY25: reported -$0.43 per share against an estimate of -$0.4514
  4. Q2 FY25: reported -$0.58 per share against an estimate of -$0.3998
  5. Q3 FY25: reported -$0.30 per share against an estimate of -$0.3675
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.3162
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.3242
  8. Q2 FY26: reported -$0.24 per share against an estimate of -$0.3232

CRBU news

  • Caroline Ryan

    Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy

  • Avi Kapoor

    Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

  • Avi Kapoor

    Nasdaq Falls Over 100 Points; US Crude Inventories Decline

  • Avi Kapoor

    Dow Tumbles 350 Points; Constellation Brands Earnings Top Views

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall as 30-Year Treasury Yield Hits 2002 High; Iran Mocks US Economy — STZ, PENG, LEVI in Focus (UPDATED)

  • Tanya Rawat

    Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why

  • Press releaseGlobe Newswire

    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

  • Press releaseGlobe Newswire

    Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Caribou Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.